^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    HER-2 positive + PD-L1 expression

    i
    Other names: ERBB2, CD340, HER-2, HER2, NEU, NGL, V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2, PD-L1, CD274, HPD-L1, PD-L1, B7H1, PDL1, Programmed death ligand 1, B7-H1, B7-H, PDCD1L1, PDCD1LG1, PDCD1 Ligand 1, B7 homolog 1, CD274 Antigen, Programmed cell death 1 ligand 1, CD274 molecule
    Entrez ID:
    2064; 29126
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    1m
    HER2 and PD-L1 Expression in Gastric and Gastroesophageal Junction Cancer: Insights for Combinatorial Targeting Approaches. (PubMed, Cancers (Basel))
    While the therapeutic implications of these observations remain unknown, these findings suggest that combination strategies targeting HER2 and PD-L1 might be directed toward distinct tumor subclones. The herein disclosed region-specific biomarker expression patterns may have important therapeutic and prognostic impacts, warranting further evaluation.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression • HER-2 positive • HER-2 overexpression • HER-2 expression • HER-2 positive + PD-L1 expression • PD-L1 expression + HER-2 overexpression • PD-L1 expression + HER-2 expression
    2ms
    Clinicopathological significance and immunotherapeutic outcome of claudin 18.2 expression in advanced gastric cancer: A retrospective study. (PubMed, Chin J Cancer Res)
    CLDN18.2-positive GC is associated with poor prognosis and worse immunotherapeutic outcomes. The combination of anti-CLDN18.2 therapy, anti-PD-L1/PD-1 therapy, and chemotherapy for GC requires further investigation.
    Retrospective data • Journal • PD(L)-1 Biomarker • IO biomarker • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • CLDN18 (Claudin 18)
    |
    PD-L1 expression • HER-2 expression • CLDN18.2 expression • CLDN18.2 positive • HER-2 positive + PD-L1 expression • CLDN1 positive • PD-L1 expression + HER-2 expression
    |
    satricabtagene autoleucel (CT041)
    2ms
    Programmed Death-Ligand1 Expression in Her-2 Positive and Triple Negative Breast Cancer (clinicaltrials.gov)
    P=N/A, N=80, Active, not recruiting, Ain Shams University | Recruiting --> Active, not recruiting | Trial completion date: Sep 2023 --> Mar 2024 | Trial primary completion date: Sep 2023 --> Mar 2024
    Enrollment closed • Trial completion date • Trial primary completion date • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression • HER-2 positive • HER-2 expression • HER-2 positive + PD-L1 expression
    7ms
    Safety and Efficacy of NK510 to Treat Gastric Cancer (clinicaltrials.gov)
    P1, N=9, Enrolling by invitation, Base Therapeutics (Shanghai) Co., Ltd.
    New P1 trial • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression • HER-2 expression • HER-2 positive + PD-L1 expression • PD-L1 expression + HER-2 expression
    |
    Herceptin (trastuzumab) • Tevimbra (tislelizumab)
    9ms
    Clinicopathologic Features and Prognostic Significance of Immunohistochemistry and In Situ Hybridization Based Molecular Classification in Gastric Carcinoma. (PubMed, J Environ Pathol Toxicol Oncol)
    Our data demonstrated a link between IHC/ISH characteristics of GC and clinical outcomes. IHC/ISH based molecular classification may be helpful in predicting the survival.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • CDH1 (Cadherin 1)
    |
    PD-L1 expression • HER-2 expression • CDH1 expression • HER-2 positive + PD-L1 expression • PD-L1 expression + HER-2 overexpression
    10ms
    Clinical Outcome and Morphology-Based Analysis of p53 Aberrant and Mismatch Repair Protein-Deficient Ovarian Clear Cell Carcinoma and Their Association With p16, HER2, and PD-L1 Expression. (PubMed, Am J Clin Pathol)
    Aberrant p53 in CCO is infrequent but associated with poor prognosis independent of stage. Presence of tumor budding could be a screening tool for p53 testing. High prevalence of HER2 and PD-L1 expression indicates the eligibility of patients with CCO for ongoing clinical trials using these therapeutic targets.
    Clinical data • Journal • Mismatch repair • PD(L)-1 Biomarker • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • MSH6 (MutS homolog 6) • PMS2 (PMS1 protein homolog 2)
    |
    PD-L1 expression • MSI-H/dMMR • HER-2 expression • HER-2 positive + PD-L1 expression • PD-L1 expression + HER-2 expression
    12ms
    Programmed Death-Ligand1 Expression in Her-2 Positive and Triple Negative Breast Cancer (clinicaltrials.gov)
    P=N/A, N=80, Recruiting, Ain Shams University | Not yet recruiting --> Recruiting
    Enrollment open • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression • HER-2 positive • HER-2 expression • HER-2 positive + PD-L1 expression • PD-L1 expression + HER-2 overexpression
    almost2years
    Programmed Death-Ligand1 Expression in Her-2 Positive and Triple Negative Breast Cancer (clinicaltrials.gov)
    P=N/A, N=80, Not yet recruiting, Ain Shams University | Trial completion date: Apr 2023 --> Aug 2023 | Initiation date: Mar 2022 --> Aug 2022 | Trial primary completion date: Mar 2023 --> Aug 2023
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression • HER-2 positive • HER-2 expression • HER-2 positive + PD-L1 expression • PD-L1 expression + HER-2 overexpression
    almost2years
    Co-occurring HER2 and PD-L1 expression in patients with HER2-positive trastuzumab-refractory gastric cancer (GC)/gastroesophageal junction adenocarcinoma (GEJA): biomarker analysis from the trastuzumab deruxtecan (T-DXd) DESTINY-Gastric03 trial (ESMO-GI 2022)
    Discordance may be attributed to tissue heterogeneity. Substantial overlap between PD-L1 positivity and HER2 positivity supports combined administration of HER2-targeted agents and checkpoint inhibitors.
    Clinical • PD(L)-1 Biomarker • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression • HER-2 positive • HER-2 amplification • HER-2 expression • HER-2 positive + PD-L1 expression • HER-2 amplification + PD-L1 expression • PD-L1 expression + HER-2 overexpression • PD-L1 expression + HER-2 expression
    |
    FoundationOne® CDx • PD-L1 IHC 22C3 pharmDx • HercepTest
    |
    Enhertu (fam-trastuzumab deruxtecan-nxki)
    2years
    PD-L1 and HER2 expression in gastric adenocarcinoma and their prognostic significance. (PubMed, Dig Liver Dis)
    PD-L1 expression is upregulated in more than half of patients with GAC. Anti-PD-L1 treatment combined with anti-HER2 therapy may benefit patients with locally advanced GAC with HER2 overexpression.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression • HER-2 positive • PD-L1 overexpression • HER-2 expression • PD-L1 negative • HER-2 positive + PD-L1 expression • PD-L1 expression + HER-2 overexpression • PD-L1 expression + HER-2 expression
    over2years
    Programmed Death-Ligand1 Expression in Her-2 Positive and Triple Negative Breast Cancer (clinicaltrials.gov)
    P=N/A, N=80, Not yet recruiting, Ain Shams University
    Clinical data • New trial • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression • HER-2 positive • HER-2 expression • HER-2 positive + PD-L1 expression • PD-L1 expression + HER-2 overexpression